Search the Newsreel

Why (ASMB) Price Action Is Critical for Tactical Trading

This article analyzes the price action of Assembly Biosciences Inc. (ASMB), highlighting a mid-channel oscillation pattern and a strong risk-reward short setup. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis to …

Assembly Biosciences (NASDAQ:ASMB) Trading Up 8.2% on Strong Earnings

Assembly Biosciences (NASDAQ:ASMB) saw its shares rise by 8.2% after reporting better-than-expected quarterly earnings, with a loss of $0.20 per share against an anticipated $0.72 loss and revenue of $13.37 million surpassing estimates of $8.60 million. Analysts have a "Moderate Buy" consensus rating with …

Assembly Biosciences earnings beat by $0.53, revenue topped estimates

Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates

Assembly Biosciences (NASDAQ:ASMB) Issues Quarterly Earnings Results, Beats Expectations By $0.52 EPS

Assembly Biosciences (NASDAQ:ASMB) reported quarterly earnings, beating analyst expectations with an adjusted loss of $0.20 per share, $0.52 better than forecast, and revenue of $13.37 million, exceeding estimates of $8.60 million. Following the news, shares rose significantly by $2.89 to $29.95 on high trading …

Assembly Biosciences (ASMB) boosts cash to $320M and narrows loss

Assembly Biosciences: Q2 Earnings Snapshot

Assembly Biosciences Projects Operations Funded Into 2029 With $75M Gilead Payment Due

Assembly Biosciences reported its Q2 2026 financial results, revealing a projected cash runway into 2029, bolstered by a recent $115 million financing and an anticipated $75 million payment from Gilead. The company is advancing its ABI-6250 program into Phase 2 studies for cholestatic liver …

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

Assembly Biosciences, Inc. – Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones – – GS-1179 (formerly ABI-1179) …

Understanding Momentum Shifts in (ASMB)

This article analyzes Assembly Biosciences Inc. (NASDAQ: ASMB), highlighting a weak near and mid-term sentiment but a neutral long-term outlook. It identifies a mid-channel oscillation pattern and an exceptional short setup targeting an 18.0% downside with minimal risk. The analysis also provides institutional trading …

Assembly Biosciences (ASMB) Expected to Post Earnings on Wednesday

Assembly Biosciences (ASMB) is anticipated to release its Q2 2026 earnings before market open on Wednesday, August 5th. Analysts project a loss of $0.70 per share on revenue of $8.6 million. The company previously reported a Q1 2026 loss of $0.54 per share, surpassing …

Eversept Partners LP Decreases Holdings in Assembly Biosciences, Inc. $ASMB

Eversept Partners LP significantly reduced its stake in Assembly Biosciences by 74.4% in the first quarter, selling 118,787 shares and retaining 40,889 shares valued at $1.14 million. Despite this, institutional investors collectively own 19.92% of the company, and analyst sentiment remains largely positive with …

Assembly Biosciences Inc (ASMB) Institutional Confidence

Assembly Biosciences Inc (ASMB) has an institutional shareholding score of 5.00, placing it 132nd out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 58.24%, marking a 171.06% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 348.54K …

Assembly Biosciences Inc (ASMB) Risk Assessment: Volatility, Financial Risk & Investment Risk

Assembly Biosciences Inc (ASMB) has a risk assessment score of 4.63, placing it 69th out of 385 in the Biotechnology & Medical Research industry. The company's beta of 1.09 indicates higher volatility compared to the S&P 500 index. The article details various risk metrics …

Assembly Biosciences Inc (ASMB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Assembly Biosciences Inc (ASMB) dividends and stock splits. It notes that no dividends have been distributed in the past five years and lists several merger-related stock split events that occurred on February 8, 2024, with a 12-to-1 ratio.

Assembly Biosciences Inc (ASMB) Cash Flow

This article provides a detailed cash flow statement for Assembly Biosciences Inc (ASMB), including operating, investing, and financing cash flows presented quarterly and annually. It features historical financial data stretching back to 2012, along with year-over-year percentage changes. The article also includes FAQs explaining …

Assembly Biosciences Market Sentiment

The article provides an overview of market sentiment signals for Assembly Biosciences (ASMB), including analyst consensus, short interest, options flow, and recent analyst actions. It highlights a "Buy" consensus from analysts with an average price target significantly above the current stock price, increasing short …

ASMB|Assembly Biosciences Inc|Price:26.680|Chg%:+0.230

This article provides a detailed financial overview of Assembly Biosciences Inc (ASMB), including its current stock price, market capitalization, P/E ratio, and recent performance. It also covers the company's financial health, technical indicators, analyst ratings, and a profile describing its focus on developing small-molecule …

Assembly Biosciences Inc (ASMB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown of Assembly Biosciences Inc (ASMB), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It provides current stock information for ASMB, including its market cap and P/E …

Avoiding Lag: Real-Time Signals in (ASMB) Movement

Quantitative Research Desk outlines real-time signals for Assembly Biosciences Inc. (ASMB), noting weak near- and mid-term sentiment but a neutral long-term outlook. The analysis highlights an exceptional risk-reward setup with potential for a 23.8% gain versus 0.3% risk, detailing institutional trading strategies including long, …

Assembly Biosciences strengthens antiviral platform with $340M liquidity and key Gilead partnership

Assembly Biosciences has successfully transformed into a well-funded antiviral development platform, backed by a significant partnership with Gilead and a robust financial position. The company's pipeline is focused on areas with high unmet medical needs like recurrent genital herpes, HDV, and cholestatic liver diseases, …